病毒学报

参考文献

[1]Ledford H.Cancer-fighting viruses win approval[J].Nature,2015,526(7575):622-623.

[2]Fukuhara H,Ino Y,Todo T.Oncolytic virus therapy:A new era of cancer treatment at dawn[J].Cancer Sci,2016,107(10):1373-1379.

[3]Russell S J,Peng K W,Bell J C.Oncolytic virotherapy[J].Nat Biotechnol,2012,30(7):658-670.

[4]Ilkow C S,Swift S L,Bell J C,Diallo J S.From scourge to cure:tumour-selective viral pathogenesis as a new strategy against cancer[J].PLoS Pathog,2014,10(1):e1003836.

[5]Huang J H,Zhang S N,Choi K J,Choi I K,Kim J H,Lee M,Kim H,Yun C O.Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12and 4-1BBL[J].Mol Ther,2009,18(2):264-274.

[6]Beug S T,Tang V A,Lacasse E C,Cheung H H,Beauregard C E,Brun J,Nuyens J P,Earl N,St-Jean M,Holbrook J.Smac mimetics and innate immune stimuli synergize to promote tumor death[J].Nat Biotechnol,2014,32(2):182-190.

[7]Cassady K A,Haworth K B,Jackson J,Markert J M,Cripe T P.To infection and beyond:the multi-pronged anti-cancer mechanisms of oncolytic viruses[J].Viruses,2016,8(2):43.

[8]Patel M R,Kratzke R A.Oncolytic virus therapy for cancer:the first wave of translational clinical trials[J].Translational Research,2013,161(4):355.

[9]Ikeda K,Wakimoto H,Ichikawa T,Jhung S,Hochberg F H,Louis D N,Chiocca E A.Complement depletion facilitates the infection of multiple brain tumors by an intravascular,replication-conditional herpes simplex virus mutant[J].J Virol,2000,74(10):4765-4775.

[10]Xu Z,Tian J,Smith J S,Byrnes A P.Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors,natural antibodies,and complement[J].J Virol,2008,82(23):11705-11713.

[11]Marchini A,Scott E M,Rommelaere J.Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade[J].Viruses,2016,8(1):9.

[12]Aurelian L.Oncolytic viruses as immunotherapy:progress and remaining challenges[J].Onco Targets Ther,2016,9:2627.

[13]Allazikani B,Banerji U,Workman P.Combinatorial drug therapy for cancer in the post-genomic era[J].Nat Biotechnol,2012,30(7):679-692.

[14]Lavanya V,Mohamed A A A,Ahmed N,Rishi A K,Jamal S.Small molecule inhibitors as emerging cancer therapeutics[J].2014,1(3):39-46.

[15]Ottolinoperry K,Diallo J S,Lichty B D,Bell J C,Mccart J A.Intelligent design:combination therapy with oncolytic viruses[J].Mol Ther,2010,18(18):251-263.

[16]Arora A,Scholar E M.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(315):971-979.

[17]Laurent A,Rose Y,Morris S,Jaquith J.Protein kinase inhibitors[J].2017.

[18]Bex A.Adjuvant sunitinib in renal-cell carcinoma[J].New Engl J Med,2017,376(9):893.

[19]Hou W,Chen H,Rojas J,Sampath P,Thorne S H.Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF[J].Int J Cancer,2014,135(5):1238-1246.

[20]Jha B K,Dong B,Nguyen C T,Polyakova I,Silverman R H.Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy[J].Mol Ther,2013,21(9):1749.

[21]News.Phase 2Study of JX-594for liver cancer[J].Jaapa.

[22]Yoo S Y,Badrinath N,Woo H Y,Heo J.Oncolytic Virus-based immunotherapies for hepatocellular carcinoma[J].Mediators Inflamm,2017,2017:12.

[23]Fu X,Tao L,Rivera A,Zhang X.Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication[J].Int J Cancer,2011,129(6):1503-1510.

[24]Alain T,Lun X,Martineau Y,Sean P,Pulendran B,Petroulakis E,Zemp F J,Lemay C G,Roy D,Bell J C.Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production[J].Proc Natl Acad Sci U S A,2010,107(4):1576-1581.

[25]Tu Y,Chen C,Pan J,Xu J,Zhou Z G,Wang C Y.The Ubiquitin proteasome pathway(UPP)in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis[J].Int J Clin Exp Pathol,2012,5(8):726-738.

[26]Carew J S,Espitia C M,Zhao W,Kelly K R,Coffey M,Freeman J W,Nawrocki S T.Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer[J/OL].Cell Death Dis,2013,4(7):e728.

[27]Diallo J,Betton B,N,Peant B,Lessard L,Le-Page C,Bertrand R,Mes-Masson A,Saad F.Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors[J].Br J Cancer,2008,99(10):1613.

[28]Yarde D N,Nace R A,Russell S J.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo[J].Exp Hematol,2013,41(12):1038-1049.

[29]Boozari B,Mundt B,Woller N,Strüver N,Gürlevik E,Schache P,Kloos A,Knocke S,Manns M P,Wirth T C.Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma[J].Gut,2010,59(10):1416.

[30]Forbes N E,Krishnan R,Diallo J S.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses[J].Front Oncol,2014,4:191.

[31]Thorne S H,Negrin R S,Contag C H.Synergistic antitumor effects of immune cell-viral biotherapy[J].Science,2006,311(5768):1780.

[32]Liu C,Erlichman C,Mcdonald C J,Ingle J N,Zollman P,Iankov I,Russell S J,Galanis E.Heat shock protein inhibitors increase the efficacy of measles virotherapy[J].Gene Ther,2008,15(14):1024-1034.

[33]Magnani L,Eeckhoute J,Lupien M.Pioneer factors:Directing transcriptional regulators within the chromatin environment[J].Trends Genet,2011,27(11):465.

[34]Forbes N E,Abdelbary H,Lupien M,Bell J C,Diallo J S.Exploiting tumor epigenetics to improve oncolytic virotherapy[J].Front Genet,2013,4:184.

[35]Nguyên L A,Abdelbary H,Arguello M,Leveille S,Bell J C,Hiscott J.322Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis[J].Cytokine,2008,105(39):14981-14986.

[36]Liu T C,Branco P C,Rabkin S D,Martuza R L.Trichostatin A and oncolytic hsv combination therapy shows enhanced antitumoral and antiangiogenic effects[J].Mol Ther,2008,16(6):1041-1047.

[37]Alvarezbreckenridge C A,Yu J,Price R,Wei M,Wang Y,Nowicki M O,Ha Y P,Bergin S,Hwang C,Fernandez S A.The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon[J].J Virol,2012,86(8):4566-4577.

[38]Cedar H,Bergman Y.Linking DNA methylation and histone modification:patterns and paradigms[J].Nat Rev Genet,2009,10(5):295-304.

[39]Okemoto K,Kasai K,Wagner B,Haseley A,Meisen H,Bolyard C,Mo X,Wehr A,Lehman A,Fernandez S.DNA demethylating agents synergize with oncolytic HSV1against malignant gliomas[J].Clin Cancer Res,2013,19(21):5952-5959.